40680-63-5

Basic information

• Product Name: methyl 6-amino-1,3-benzodioxole-5-carboxylate
• Synonyms: 1,3-benzodioxole-5-carboxylic acid, 6-amino-, methyl ester; Methyl 6-amino-1,3-benzodioxole-5-carboxylate
• CAS NO: 40680-63-5
• Molecular Formula: C₉H₉NO₄
• Molecular Weight: 195.1721
• Mol File: 40680-63-5.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 337.1°C at 760 mmHg
• Flash Point: 184.8°C
• Density: 1.386g/cm³
• Vapor Pressure: 0.000107mmHg at 25°C
• Refractive Index: 1.604
• CAS DataBase Reference: methyl 6-amino-1,3-benzodioxole-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 6-amino-1,3-benzodioxole-5-carboxylate(40680-63-5)
• EPA Substance Registry System: methyl 6-amino-1,3-benzodioxole-5-carboxylate(40680-63-5)

Safety Data

• Hazardous Substances Data: 40680-63-5(Hazardous Substances Data)

Upstream product

• 721-00-6 methyl 6-nitrobenzo[d][1,3]dioxole-5-carboxylate 
• 7647-01-0 hydrogenchloride 
• 64-19-7 acetic acid 
• 326-56-7 methyl 3,4-methylenedioxybenzoate 
• 94-53-1 Piperonylic acid 
• 712-97-0 6-nitro-1,3-benzodioxole-5-carbaldehyde 
• 716-32-5 6-nitrobenzo[d][1,3]dioxole-5-carboxylic acid 

Downstream Products

• 111054-06-9 1-(6-Amino-benzo[1,3]dioxol-5-yl)-2-(triphenyl-λ⁵-phosphanylidene)-ethanone 
• 1266868-75-0 ([1,3]dioxolo[4,5-g]quinazolin-8-yl)-(3'-chloro-4'-fluorophenyl)amine hydrochloride 
• 1266869-09-3 ([1,3]dioxolo[4,5-g]quinazolin-8-yl)-(4'-bromo-2'-fluorophenyl)amine hydrochloride 
• 1256394-35-0 4-(N-methyl-3-chloro-4-fluoroanilino)-6,7-methylenedioxyquinazoline 
• 1256394-36-1 4-(N-methyl-4-bromo-2-fluoroanilino)-6,7-methylenedioxyquinazoline 
• 72700-23-3 8-chloro-[1,3]dioxolo[4,5-g]quinazoline 
• 20197-55-1 6,8-dichloro-2H-[1,3]dioxolo[4,5-g]quinazoline 
• 20332-16-5 4,5-methylenedioxyanthranilic acid 
• 1448676-77-4 6-cyclobutyl-8-(4-(2-methoxyphenyl)piperazin-1-yl)-[1,3]dioxolo[4,5-g]quinazoline 
• 94-53-1 Piperonylic acid 
• 116605-08-4 7-amino-6-(4,4'-dichloro-benzhydryl)-7H-[1,3]dioxolo[4,5-g]quinazolin-8-one 
• 110152-88-0 7-amino-6-(3,4,5-trimethoxy-phenyl)-7H-[1,3]dioxolo[4,5-g]quinazolin-8-one 
• 109126-90-1 7-amino-6-phenyl-7H-[1,3]dioxolo[4,5-g]quinazolin-8-one 
• 109773-42-4 3-(Triphenyl-λ⁵-phosphanylidene)-3H-[1,3]dioxolo[4,5-g]cinnolin-4-one 

Relevant articles and documents

New Size-Expanded Fluorescent Thymine Analogue: Synthesis, Characterization, and Application

Here, the synthesis, photophysical characterization, and application of a new size-expanded thymine nucleoside, dioxT, is described. dioxT has desirable qualities as a T surrogate, including excellent quantum yield (0.36) and high environmental sensitivity. When incorporated into single- and double-stranded DNA, dioxT showed excellent photophysical characteristics including a high quantum yield (average 0.20), and unlike BgQ, demonstrated dependence on neighboring bases without significant destabilization of the duplex. Interestingly, the matched base pair of adenine (A) and dioxT has the unique property that it exhibits higher fluorescence than mismatched base pairs, and dioxT has self-quenching effects. As one example of the possible applications of these promising features, single nucleoside polymorphism typing is demonstrated for discrimination of A by using dioxT. The results suggest that dioxT can be used for a broad range of applications in chemical biology.

ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I' PATHWAY AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

As the PI3K/mTOR inhibitor tricyclic compound, its preparation and use

The invention discloses a tricyclic compound as a PI3K/mTOR inhibitor. The tricyclic compound is a compound with the general formula (I) in the specification, wherein Ar is selected from aryl or heteroaryl; X, Y and Z are independently selected from O, CR2R3 and NR4 respectively; Q is selected from O, CR2R3 and NR4 or does not exists; R1 represents C1-C6 alkyl; n is selected from integers from 0 to 4; when n is more than or equal to 2, two R1 and a morpholine cycle can be combined into a combined cycle, a bridge cycle or a spiral cycle; R2 and R3 are selected from hydrogen and C1-C6 alkyl; R4 is selected from hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, heterocyclic radical, acyl and sulfonyl. The invention further discloses a perpetration method of the compound with the general formula (I) as well as a pharmaceutical composition and application of the compound with the general formula (I).